💪👏
RT @cpontesg: @quequesierra Claro: Applicability and added value of novel methods to improve drug development in rare diseases https://t.c…
@quequesierra Claro: Applicability and added value of novel methods to improve drug development in rare diseases https://t.co/Ov0hbPlIq7 Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological u
RT @cpontesg: Last year we also concluded that evidence supporting orphan drugs approval in EU had many uncertainties: weak protection agai…
Last year we also concluded that evidence supporting orphan drugs approval in EU had many uncertainties: weak protection against stat errors, designs unsuited to conclude causality, intermediate variables, lack of a priorism and insufficient safety data.
RT aHUSAllianceAct Interesting read on #clinicaltrials for #rarediseases. There are opportunities for improvement, including use of available methods & designs that work better for small #patient populations. Proposed model to cluster medical condition
Interesting read on #clinicaltrials for #rarediseases. There are opportunities for improvement, including use of available methods & designs that work better for small #patient populations. Proposed model to cluster medical conditions w/ similar #clini
"Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties". Pontes C, Fontanet JM, Vives R, et al. @pubmedhealth https://t.co/QZLwkroZrj https://t.co/97ZLv0uymO
RT @rfhb: Identifying patients’ disease courses, facilitating to apply better research methods and to address uncertainties - great work: h…
Identifying patients’ disease courses, facilitating to apply better research methods and to address uncertainties - great work: https://t.co/ZAWUQs9Tgd @EMA_News
RT @cpontesg: Our proposal for grouping orphan medical conditions with similar methodological requirements for trial design and the analysi…
Congrats, amiga (amigos)!! Buen trabajo!
Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties @cpontesg @MGValent @AsterixFp7 @UABBarcelona #equipAsterixBCN#enhorabona https://t.co/SGYbAhodgn
RT @cpontesg: Our proposal for grouping orphan medical conditions with similar methodological requirements for trial design and the analysi…
RT @cpontesg: Our proposal for grouping orphan medical conditions with similar methodological requirements for trial design and the analysi…
RT @cpontesg: Our proposal for grouping orphan medical conditions with similar methodological requirements for trial design and the analysi…
RT @cpontesg: Our proposal for grouping orphan medical conditions with similar methodological requirements for trial design and the analysi…
Our proposal for grouping orphan medical conditions with similar methodological requirements for trial design and the analysis of current regulatory uncertainties in OMP authorizations are both online. A long way with happy end. @AsterixFp7 #UAB #parctauli